Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis
Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis have?
Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis has 95 citations in the OpenAlex counts ScholarIQ stores.
When was Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis published?
Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis has 2017 year in the ScholarIQ index.
What is the open-access status of Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis?
Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis has closed oa status in the ScholarIQ index.
What is the DOI of Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis?
The DOI for Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis is on the source record.
What is the PMID of Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis?
The PMID for Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis is on the source record.
What is the OpenAlex record for Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis?
The OpenAlex for Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis is on the source record.